Dengue fever has become an imminent threat to international public health because of global
warming and climate change. The World Health Organization proclaimed that more than 50% of the
world’s population is at risk of dengue virus (DENV) infection. Therefore, developing a clinically approved
vaccine and effective therapeutic remedy for treating dengue fever is imperative. Peptide drug
development has become a novel pharmaceutical research field. This article reviews various peptidesbased
antimicrobial agents targeting three pathways involved in the DENV lifecycle. Specifically, they
are peptide vaccines from immunomodulation, peptide drugs that inhibit virus entry, and peptide drugs
that interfere with viral replication. Many antiviral peptide studies against DENV have been conducted
in animal model trials, and progression to clinical trials for these promising peptide drugs is anticipated.
Keywords: Dengue fever, dengue virus, peptide drug, peptide vaccine, antimicrobial agents, clinical trials.
open access plus
Rights & PermissionsPrintExport